Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

229
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
229
Multiple Comparison Tests01:13

Multiple Comparison Tests

4.0K
Multiple comparison test, abbreviated as MCT, is a post hoc analysis generally performed after comparing multiple samples with one or more tests. An MCT will help identify a significantly different sample among multiple samples or a factor among multiple factors.
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
4.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
The Mantel-Cox Log-Rank Test01:19

The Mantel-Cox Log-Rank Test

446
The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of...
446
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

3.4K
A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
3.4K
Receiver Operating Characteristic Plot01:15

Receiver Operating Characteristic Plot

285
A ROC (Receiver Operating Characteristic) plot is a graphical tool used to assess the performance of a binary classification model by illustrating the trade-off between sensitivity (true positive rate) and specificity (false positive rate). By plotting sensitivity against 1 - specificity across various threshold settings, the ROC curve shows how well the model distinguishes between classes, with a curve closer to the top-left corner indicating a more accurate model. The area under the ROC curve...
285

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China.

Frontiers in urology·2026
Same author

A case of SAPHO syndrome with wrist involvement as the first presentation and response to tofacitinib therapy.

Joint bone spine·2025
Same author

Corrigendum: A retrospective study of paraganglioma of the urinary bladder and literature review.

Frontiers in surgery·2025
Same author

Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study.

Signal transduction and targeted therapy·2024
Same author

[Retracted] Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.

Oncology reports·2024
Same author

A retrospective study of paraganglioma of the urinary bladder and literature review.

Frontiers in surgery·2024

Related Experiment Video

Updated: Jul 28, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K

The direct prognosis comparison of

Zhen Liang1, Chen Yuliang1, Ming Zhu1

  • 1Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

European Journal of Medical Research
|June 2, 2023
PubMed
Summary

Low-dose-rate brachytherapy (LDR) offers improved biochemical relapse-free survival (bRFS) for intermediate-risk prostate cancer (IRPC) patients compared to radical prostatectomy (RP), with similar overall survival rates.

Keywords:
Comparative effectivenessLow-dose-rate brachytherapyProstatic neoplasmsRadical prostatectomyTreatment outcomes

More Related Videos

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K

Related Experiment Videos

Last Updated: Jul 28, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.4K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K

Area of Science:

  • Urology
  • Oncology
  • Radiation Oncology

Background:

  • Intermediate-risk prostate cancer (IRPC) requires careful treatment selection.
  • Radical prostatectomy (RP) and low-dose-rate brachytherapy (LDR) are primary treatment options for IRPC.

Purpose of the Study:

  • To compare clinical outcomes between RP and LDR in IRPC patients.
  • To evaluate biochemical relapse-free survival (bRFS), clinical relapse-free survival (cRFS), cancer-specific survival (CSS), and overall survival (OS).

Main Methods:

  • Retrospective analysis of 361 IRPC patients treated between 2014 and 2021.
  • Comparison of 160 patients undergoing RP versus 201 patients undergoing Iodine-125 LDR.
  • Statistical analysis including log-rank tests and Cox regression for survival outcomes.

Main Results:

  • LDR demonstrated significantly higher 5-year (83.2% vs 70.2%) and 8-year (68.9% vs 63.1%) bRFS compared to RP.
  • No significant differences were observed in cRFS, CSS, or OS between the RP and LDR groups.
  • Independent predictors for worse bRFS included prostate volume ≤ 30 ml, positive surgical margins, and >50% positive biopsy cores.

Conclusions:

  • Low-dose-rate brachytherapy (LDR) is a viable treatment for intermediate-risk prostate cancer (IRPC).
  • LDR provides superior bRFS compared to radical prostatectomy (RP).
  • LDR achieves comparable cRFS, CSS, and OS rates to RP in IRPC patients.